Study of Anitocabtagene-autoleucel in Participants With Relapsed Refractory Multiple Myeloma

Master Protocol for the Phase 1 Study of Cell Therapies for the Treatment of Patients With Relapsed Refractory Multiple Myeloma, Including Long-term Safety Follow-up

Master protocol for cell therapy, Phase 1 proof-of-concept studies in relapsed and refractory multiple myeloma and includes long-term safety follow-up.

Inclusion Criteria:

• Relapsed and refractory Multiple Myeloma treated with at least 3 prior regimens of system therapy including Proteosome Inhibitor (PI), immunomodulatory drugs (IMiD), and anti-CD38 antibody (CD38mab); or has "triple-refractory" disease
• Documented measurable disease
• Adequate organ function
• Life expectancy > 12 weeks, Eastern Cooperative Group Performance Status 0-1

Exclusion Criteria:

• Plasma Cell Leukemia or History of Plasma Cell Leukemia
• Patients with a history of severe hypersensitivity to DMSO should be excluded
• Contraindication to fludarabine or cyclophosphamide
• Severe uncontrolled intercurrent illness (e.g., infection) or laboratory abnormalities
• Active central nervous system disease involvement by malignancy or active CNS pathology